Kratom's legal status in the United States has been changing rapidly through 2026, with a major federal scheduling action taken just weeks ago, alongside a wide and shifting patchwork of state level battles over existing Kratom Consumer Protection Act frameworks. Some states are tightening restrictions toward outright bans, one state has reversed a prior ban entirely, and the federal government has moved for the first time to specifically target concentrated and synthetic derivatives rather than the plant itself. This article walks through the current federal action in detail, the state by state legal picture, the reasoning behind the recent scheduling push, what the Kratom Consumer Protection Act framework actually requires, and what all of this means for anyone trying to follow the topic in real time.
A Quick Background on Kratom and Why It Became a Legal Flashpoint
Kratom, derived from the leaves of the tropical evergreen plant Mitragyna speciosa, has been used for generations in parts of Southeast Asia, where the plant is native. In the United States, it has grown into a widely available product sold as tea, powder, capsules, and extract, often marketed around energy, mood, and general wellbeing, and it has also become a genuine flashpoint in drug policy debates because its effects and risk profile do not fit neatly into existing regulatory categories.
Part of the ongoing legal complexity comes from kratom's chemistry. The plant naturally contains alkaloids, most notably mitragynine and, in much smaller natural concentrations, 7-hydroxymitragynine, generally referred to as 7-OH. In recent years, manufacturers have begun producing highly concentrated or chemically modified versions of 7-OH, delivered through fast absorption formats such as sublingual tablets, rapid dissolve tabs, and gummies. These enhanced products behave very differently from traditional botanical kratom leaf and have become the primary focus of the most recent federal regulatory action, rather than kratom broadly.
This distinction, between ordinary leaf kratom and concentrated or synthetic 7-OH products, is the single most important thing to understand about the current legal landscape, since a lot of confusion in public conversation comes from treating kratom as one single, uniform product category when the regulatory reality increasingly treats it as two very different things.
Federal Action: DEA Moves on 7-OH
The most significant recent development came at the federal level. Two Notices of Intent were sent to the Federal Register on July 1, 2026. One addressed 7-hydroxymitragynine above a specified threshold, and the second addressed related synthetic substances, specifically mitragynine pseudoindoxyl, MGM-15, and MGM-16, none of which occur naturally in the kratom plant itself. These notices were published in the Federal Register on July 6, 2026, with the temporary scheduling orders expected to take effect roughly 30 days later, placing the likely effective date in early August 2026.
Importantly, this action is narrower in scope than a blanket kratom ban. The DEA's action specifically targets enhanced, concentrated, synthetic, and semi synthetic 7-OH products, not ordinary botanical kratom leaf containing only naturally occurring trace amounts of 7-OH below the specified threshold. This means the millions of people who use traditional kratom leaf products are not the direct target of this particular scheduling action, even though public discussion often treats the two categories as interchangeable.
Alongside the DEA's notice, HHS opened a 30 day public comment period specifically on the proposed 7-OH threshold used in the scheduling order, giving manufacturers, advocacy groups, medical professionals, and the public a formal window to weigh in before the threshold is finalized.
The Regulatory Timeline Leading Up to This Action
This move did not happen suddenly. The regulatory background stretches back well over a year. The FDA formally recommended Schedule I classification for concentrated 7-OH products to the DEA back on July 29, 2025, but the DEA spent months reviewing that recommendation before taking formal action. The Administrator of the DEA transmitted formal notice of intent to place 7-hydroxymitragynine above a specified threshold in Schedule I to the Assistant Secretary for Health at HHS by letter dated February 24, 2026. HHS responded by letter dated March 6, 2026, confirming that, based on FDA review, there were no active investigational new drug applications or approved new drug applications for these substances, and stating that HHS had no objection to temporary Schedule I placement.
Congressional pressure also played a visible role in pushing the process forward. In March 2026, a member of Congress sent a formal letter to the DEA administrator urging immediate emergency scheduling of 7-OH, describing it as a chemically manipulated derivative of kratom with opioid like effects. That letter specifically flagged the growing presence of fast absorption formats such as sublingual and chewable tablets, rapid dissolve tablets, and gummies, noting that these formats deliver 7-OH into the bloodstream within minutes, producing intense, opioid like euphoria that dissipates quickly and encourages compulsive redosing. Legislative language accompanying government funding legislation echoed this concern, expressing grave concern regarding the proliferation of chemically manipulated derivatives of mitragynine, including high concentration 7-hydroxymitragynine products, and calling for swift administrative action consistent with the earlier FDA and HHS recommendation.
Why the DEA Says This Action Was Necessary
To justify emergency style temporary scheduling, the DEA is required to demonstrate that placing a substance in Schedule I is necessary to avoid an imminent hazard to public safety. The DEA's notice cites a range of health and safety risks associated with these substances, including cardiotoxicity, hepatic and renal toxicity, respiratory depression, neurological effects, and physical dependence and withdrawal, describing them as carrying risks consistent with other opioid receptor agonists.
Adverse event and poison control data formed a significant part of the justification. A query of the FDA's adverse event reporting system dashboard in August 2025 showed a relatively low historical case count, with just one case in 2023 and two cases in 2024 involving 7-hydroxymitragynine. A follow up query in February 2026 revealed a sharp increase, with the 2025 total climbing to 66 cases and 17 additional new cases already logged in early 2026. Of these cases, the most common issues reported involved drug dependence and withdrawal syndrome. Separately, poison control center data showed 1,690 exposure calls involving kratom between January and July 2025, described as a significant increase compared to the equivalent period in 2024.
This combination, a documented spike in adverse events tied specifically to concentrated 7-OH products, alongside the emergence of fast acting delivery formats designed to maximize absorption speed, forms the core justification the DEA used to move forward with temporary scheduling rather than waiting for the standard, longer rulemaking process.
What Happens Once the Temporary Order Takes Effect
Once finalized, the practical impact for anyone handling these specific substances is significant. Once the temporary scheduling orders take effect, the manufacture, distribution, sale, and possession of covered 7-OH substances will become subject to the criminal, civil, and administrative provisions of the Controlled Substances Act, the same legal framework that governs substances like heroin and LSD at the Schedule I level.
For businesses currently selling enhanced or concentrated 7-OH products, this represents an existential shift, since Schedule I placement effectively criminalizes the product line rather than simply regulating it. For consumers who specifically use these concentrated formats, it means a previously accessible product will become illegal to possess in most circumstances once the order is finalized and published.
As of right now, though, nothing has legally changed yet at the federal level. As of July 1, 2026, 7-hydroxymitragynine is not federally scheduled or banned, and it remains technically legal to sell and possess under federal law while the temporary scheduling process plays out through its remaining steps, including the current public comment period.
State Level Picture: A Patchwork That Keeps Shifting
While the federal action targets 7-OH specifically, individual states have been moving in very different directions on kratom broadly for years, and 2026 has brought a particularly active stretch of legislative activity, with some states tightening restrictions and at least one loosening them.
States with full bans
As of July 2026, eight states fully ban kratom outright: Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, Connecticut, and Tennessee. Tennessee is the most recent addition to that list. Tennessee's ban legislation, HB1649/SB1656, was signed into law May 7, 2026 as Public Chapter 950, and took effect July 1, 2026, making it one of the most recent and closely watched state level prohibition actions of the year.
A reversal in the other direction
Not every state has been moving toward restriction. Rhode Island became the first state to reverse an existing kratom ban, with the reversal taking effect April 1, 2026. Rhode Island had banned kratom since 2017, and the new regulatory framework instead allows kratom sales to adults aged 21 and older, with labeling, testing, and product safety requirements modeled specifically on the Kratom Consumer Protection Act structure used in other regulated states. Advocacy groups pushing for the reversal argued that the original ban had simply pushed consumers toward unregulated, unsafe sources rather than actually reducing use, and had created patchwork enforcement problems without meaningfully reducing dependence.
KCPA states facing rollback threats
Several states that currently regulate kratom through Kratom Consumer Protection Act frameworks are facing active bills in 2026 that would repeal those frameworks entirely and shift toward outright prohibition instead:
- South Carolina passed its own Kratom Consumer Protection Act, but entered 2026 facing new bills that would swing back toward prohibition. H.4636, along with related bills in the same legislative cluster, proposes adding kratom to Schedule I and repealing the state's existing KCPA. As of April 2026, three related bills, H.4636, H.4641, and H.4648, remained in committee, though later reporting suggested the ban momentum in South Carolina appeared to be slowing somewhat compared to earlier in the year.
- Utah, the state that originally created the Kratom Consumer Protection Act model back in 2019, is now facing SB 45, which would repeal Utah's own Kratom Consumer Protection Act and reclassify kratom derived alkaloids as Schedule I controlled substances, a notable reversal given the state's historical role as the template setter for regulated kratom access.
- Arizona faced an amendment added to an otherwise unrelated bill that would add kratom, 7-hydroxymitragynine, and mitragynine, along with any substance derived from the Mitragyna speciosa plant, to Arizona's controlled substances list, while simultaneously repealing Arizona's existing Kratom Consumer Protection Act, which had been in place since 2019.
- South Dakota's SB 77 sought to ban kratom and kratom products outright and establish penalties for violations, but legislative tracking shows the bill failed a Senate floor vote on January 22, 2026, meaning the ban did not move forward, at least for the current session.
- Kansas moved to ban all forms of kratom, according to an April 27, 2026 legislative update.
- Kentucky was reported likely to ban kratom sales specifically, though not possession, according to an April 14, 2026 update, representing a narrower approach than an outright possession ban.
- North Carolina added a kratom ban into an otherwise unrelated bill, according to a June 29, 2026 update, illustrating a pattern seen in several states where kratom restrictions get attached to broader legislative vehicles rather than moving as standalone bills.
- Idaho's 2026 legislative session ended on April 2 without a kratom ban passing, despite a bill, HB968, having been introduced in January proposing to classify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances.
- California has seen a somewhat different pattern, where the California Department of Public Health has continued removing kratom and 7-OH products from shelves through agency action, despite there being no actual law prohibiting either substance in the state, illustrating how enforcement and formal legal status can diverge in practice.
Where the KCPA model remains the norm
Despite all of this legislative turbulence, more than thirty states currently regulate kratom under Kratom Consumer Protection Act frameworks rather than banning it outright. The template traces back to Utah, which enacted the first Kratom Consumer Protection Act in 2019, establishing the now familiar structure of age gating, alkaloid concentration caps, labeling requirements, and vendor registration. Adoption accelerated significantly between 2022 and 2024, with Georgia, Arizona, Nevada, Oregon, Virginia, Colorado, Texas, Mississippi, and Oklahoma among the states adding their own versions of the framework during that period. Notably, in 2021, the FDA itself formally recommended against scheduling kratom broadly to HHS and DEA, citing insufficient evidence for Schedule I placement at that time, a recommendation that stands in contrast to the more recent, narrower action targeting concentrated 7-OH specifically.
What a Kratom Consumer Protection Act Typically Requires
For readers unfamiliar with the framework, a state level Kratom Consumer Protection Act generally takes a regulate rather than prohibit approach, treating kratom more like a controlled dietary supplement than a banned substance. Typical requirements found across most state versions of the law include:
- Age verification, commonly restricting sales to adults 21 and older, though some earlier versions of the law set the threshold at 18
- Clear product labeling listing the ingredients used in manufacturing the product
- Disclosure of the specific amount of mitragynine and 7-hydroxymitragynine contained in the product
- Identification of the vendor or processor responsible for distributing the product, including a name and street address
- Any necessary precautionary statements regarding safety and effectiveness
- A required statement that the product is not intended to diagnose, treat, cure, or prevent any medical condition or disease
- A prohibition on selling or transferring the product to anyone under the applicable legal age
- Civil penalties for retailers found in violation of labeling or sale requirements, with fines that vary meaningfully between states
These frameworks are generally understood as an attempt to bring consistency, testing, and basic consumer protection to a product category that had previously operated with very little oversight, without going as far as full prohibition.
Where This Leaves Kratom's Legal Status Right Now
Pulling the current picture together as of mid July 2026:
- Kratom leaf itself remains federally legal, with no federal scheduling currently in place
- 7-OH above a specified threshold, along with three related synthetic compounds, is in the process of temporary federal scheduling, expected to take effect in early August 2026 pending the outcome of the current public comment period
- Eight states currently ban kratom outright, with Tennessee the most recent addition as of July 1, 2026
- One state, Rhode Island, has reversed a prior ban in favor of a regulated framework, becoming the first state to do so
- More than thirty states currently regulate kratom through Kratom Consumer Protection Act style frameworks, though several of those frameworks face active repeal or rollback bills moving through 2026 legislative sessions
- At least one high profile ban attempt, in South Dakota, failed at the floor vote stage this year, showing that rollback efforts are not automatically succeeding everywhere they are introduced
- The overall national picture remains a genuine, actively shifting patchwork, and legal status can differ significantly depending on which state someone is in, and can change within a matter of weeks as sessions progress
Frequently Asked Questions
Is kratom federally illegal right now?
No. As of July 2026, kratom itself is not federally scheduled or banned under the Controlled Substances Act, though several states ban it under their own separate state laws.
Is 7-OH banned yet?
Not fully, and not immediately. The FDA recommended Schedule I classification back in 2025, and the DEA has now filed formal Notices of Intent covering both 7-OH above a specified threshold and three related synthetic substances, but the temporary scheduling order was not yet in effect as of the July 1, 2026 filing date, with an effective date expected roughly 30 days after the July 6, 2026 Federal Register publication.
Does the new DEA action ban regular kratom leaf products?
No. The action specifically targets enhanced, concentrated, synthetic, and semi synthetic 7-OH products rather than ordinary botanical kratom leaf, which contains only naturally occurring trace amounts of 7-OH well below the specified threshold covered by the notice.
Which states currently ban kratom entirely?
As of July 2026, Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, Connecticut, and Tennessee fully ban kratom.
Has any state reversed a kratom ban?
Yes. Rhode Island reversed its kratom ban effective April 1, 2026, becoming the first state to do so, replacing it with a regulated framework modeled on other states' Kratom Consumer Protection Acts.
What is happening with kratom legislation in South Carolina right now?
South Carolina has an existing Kratom Consumer Protection Act, but multiple 2026 bills, including H.4636, H.4641, and H.4648, aim to repeal it and reclassify kratom as Schedule I. Those bills remained in committee as of the most recent tracking update, though momentum behind them was reported to be slowing somewhat.
Why did Utah, the state that created the Kratom Consumer Protection Act model, end up considering repealing its own law?
Utah's SB 45 proposes repealing the state's original 2019 Kratom Consumer Protection Act and reclassifying kratom derived alkaloids as Schedule I, reflecting a broader shift in legislative sentiment in some states even where the regulate rather than ban approach originated.
Where can someone follow ongoing legislative changes?
Given how frequently kratom laws are changing at both the state and federal level in 2026, checking official state legislature websites, the Federal Register, and direct DEA and FDA public announcements is the most reliable way to get current, unfiltered information rather than relying on secondhand summaries, since the legal picture in any specific state can shift within a matter of weeks as legislative sessions continue to move forward.